Wuhan BravoVax  Co., Ltd. (hereinafter referred to as Wuhan BravoVax), founded in 2012, is a "national high-tech enterprise" specializing in the R & D, manufacturing and marketing of high-end human vaccines. It has won the "Hubei new vaccine and recombinant protein engineering laboratory", "Hubei enterprise technology center", "Hubei biosafety laboratory" "Wuhan gazelle enterprise" and other qualifications or honors. It is a member of the vaccine enterprise alliance of developing countries (DCVMN). The company is committed to developing and commercialization of heavy products such as multivalent rotavirus vaccine, new pneumococcal conjugate vaccine, recombinant New Coronavirus vaccine, broad spectrum HPV vaccine, recombinant herpes zoster vaccine, and strives to provide vaccine products for China and the world in accordance with the international vaccine product industry regulation requirements.